Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have received an average recommendation of “Buy” from the nineteen research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $68.25.
A number of analysts recently weighed in on NBIX shares. ValuEngine upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $67.00 price target on shares of Neurocrine Biosciences in a research note on Monday, May 22nd. BMO Capital Markets reiterated an “outperform” rating and set a $72.00 price target on shares of Neurocrine Biosciences in a research note on Monday, April 17th. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $80.00 price target on shares of Neurocrine Biosciences in a research note on Monday, April 17th.
In other news, insider Haig P. Bozigian sold 22,500 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the completion of the transaction, the insider now owns 154,601 shares in the company, valued at approximately $7,730,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Malcolm Lloyd-Smith sold 9,960 shares of the firm’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $53.63, for a total transaction of $534,154.80. Following the transaction, the insider now owns 17,997 shares of the company’s stock, valued at $965,179.11. The disclosure for this sale can be found here. Insiders sold a total of 51,194 shares of company stock valued at $2,629,755 in the last quarter. Insiders own 4.80% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Emory University acquired a new position in Neurocrine Biosciences during the second quarter valued at $1,349,000. TIAA CREF Investment Management LLC increased its position in Neurocrine Biosciences by 21.1% in the second quarter. TIAA CREF Investment Management LLC now owns 329,035 shares of the company’s stock valued at $15,136,000 after buying an additional 57,371 shares during the period. Teachers Advisors LLC increased its position in Neurocrine Biosciences by 10.8% in the second quarter. Teachers Advisors LLC now owns 91,550 shares of the company’s stock valued at $4,211,000 after buying an additional 8,903 shares during the period. Stephens Inc. AR acquired a new position in Neurocrine Biosciences during the second quarter valued at $207,000. Finally, Alliancebernstein L.P. increased its position in Neurocrine Biosciences by 3.1% in the second quarter. Alliancebernstein L.P. now owns 956,675 shares of the company’s stock valued at $44,007,000 after buying an additional 28,660 shares during the period. Hedge funds and other institutional investors own 96.48% of the company’s stock.
Neurocrine Biosciences (NASDAQ:NBIX) opened at 53.85 on Monday. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $55.38. The company’s 50 day moving average is $48.33 and its 200 day moving average is $46.68. The stock’s market cap is $4.75 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million for the quarter, compared to analysts’ expectations of $0.61 million. During the same period in the prior year, the company posted ($0.46) EPS. On average, equities research analysts expect that Neurocrine Biosciences will post ($2.45) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was reported by BNB Daily and is the property of of BNB Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/neurocrine-biosciences-inc-nasdaqnbix-given-consensus-recommendation-of-buy-by-brokerages-updated-updated-updated.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.